FDA Releases Draft Guidance on CLIA Waiver Criteria

Summary

The Food and Drug Administration (FDA) has made available a draft guidance document proposing alternative criteria for obtaining a waiver under the Clinical Laboratory Improvement Amendments of 1988 (CLIA), which would replace criteria proposed by the Health Care Financing Administration (HCFA) and the Centers for Disease Control and Prevention (CDC).